By Kailyn Rhone
Shares of Harrow slipped after the pharmaceutical company reported third-quarter results that missed analysts' expectations.
The stock closed down 25%, at $39.10, in after-hours trading Wednesday. For the year, shares are up 362%.
The Nashville company reported a third-quarter loss of $4.2 million, or 12 cents a share, compared with a loss of $4.4 million, or 13 cents a share, for the same period a year earlier. Analysts polled by FactSet expected a loss of five cents.
Revenue rose 44%, to $49.3 million. That fell short of the $52.8 million expected by analysts polled by FactSet.
Chief Executive Mark L. Baum said the company sees strong performance for the fourth quarter and expects "a record-breaking finish" for the year.
Write to Kailyn Rhone at kailyn.rhone@wsj.com
(END) Dow Jones Newswires
November 13, 2024 17:37 ET (22:37 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。